Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Alligator Bioscience AB Full Year Report 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
By: PR Newswire Association LLC. - 16 Feb 2018 | Back to overview list |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLM, Feb. 16, 2018 /PRNewswire/ -- The Janssen collaboration continues, milestone payment of 6 MUSD triggered Significant events, October-December • Alligator Bioscience recorded a revenue of USD 6 million from Janssen, coupled to a decision to start combination study with ADC-1013/JNJ-64457107. This milestone payment was received in January 2018. • A decision was taken to expand the management team with Chief Medical Officer Charlotte A Russell, MD, PhD and Vice President Discovery Peter Ellmark, Associate Professor. • Results from Alligator Bioscience's clinical Phase I study presented, supporting a continued clinical development of ADC-1013. • Aptevo Therapeutics and Alligator Bioscience announced the tumor antigen 5T4 as the second target for the drug candidate ALG.APV-527. Events after the end of the period • Theradex Oncology contracted as clinical CRO for the upcoming clinical study with ATOR-1015. • Anudharan Balendran appointed VP Business Development starting 1 May 2018. • Janssen clinical Phase I study with ADC-1013 ongoing. Financial summary October-December • Net Sales, SEK 51.3 million (6.4). • Operating result, SEK 10.7 million (-22.1). • Result for the period, SEK 12.5 million (-19.4). • Result per share, SEK 0.18 (-0.31). • Cash, cash equivalents and bonds, SEK 547 million (659). January-December • Net Sales, SEK 56.9 million (58.2). • Operating result, SEK -62.3 million (-56.1). • Result for the period, SEK -63.8 million (-48.4). • Result per share, SEK -0.89 (-0.80). • Cash flow for the period before investments in bonds, SEK -108.7 million and after -183.2 (287.1). • During the period 1,275,000 warrants (330,000) were exercised for an equivalent number of shares. Financial summary (Group)
Conference call All interested parties are invited to participate in a telephone conference which will include a presentation of the Full Year Report. The event will be hosted by CEO Per Norlén and the presentation will be held in English. When: 1:15 pm CET Friday 16 February 2018 The conference call will be made available on the company´s website after the call: www.alligatorbioscience.com. The information was submitted for publication, through the agency of the contact persons set out above, at 8:00 a.m. CET on 16 February 2018. About Alligator Bioscience For further information, please contact: Alligator Bioscience AB (publ) 556597-8201 This information was brought to you by Cision http://news.cision.com The following files are available for download:
View original content:http://www.prnewswire.com/news-releases/alligator-bioscience-ab-full-year-report-2017-300599984.html SOURCE Alligator Bioscience |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright 2018 PR Newswire Association LLC. | Back to overview list |